CCK-1 receptor blockade for treatment of biliary colic: A pilot study

A. Malesci, R. Pezzilli, M. D'Amato, L. Rovati

Research output: Contribution to journalArticle

Abstract

Background: Loxiglumide is a potent and selective cholecystokinin-1 (CCK-1) receptor antagonist able to inhibit gall-bladder contraction. Aim: To assess the effect of CCK-1 receptor blockade on the pain of patients with biliary colic. Patients and methods: Fourteen patients with biliary colic but no suspicion for acute cholecystitis, were randomly and blindly assigned to loxiglumide (50 mg i.v.) or hyoscine-N-butyl bromide (20 mg i.v.) treatment. Pain intensity was monitored by a Visual Analogue Scale. Patients with less than 80% response at 30 min, were retreated with a second injection of the same compound. Results: Reduction in pain score (mean ± S.E.M.) was faster and significantly greater in patients treated with loxiglumide (n = 7) than in controls (n = 7): 88 ± 7% vs. 47 ± 12% after 20 min, P <0.05; 92 ± 6% vs. 49 ± 13%, after 30 min, P <0.05. Only one of seven patients treated with loxiglumide needed a second injection at 30 min (vs. six of seven controls, P <0.05). No adverse effect was observed after either treatment. Conclusions: Loxiglumide is highly effective in obtaining pain relief in patients with biliary colic. The analgesic effect of CCK-1 receptor blockade is superior to that of a conventional anticholinergic treatment.

Original languageEnglish
Pages (from-to)333-337
Number of pages5
JournalAlimentary Pharmacology and Therapeutics
Volume18
Issue number3
DOIs
Publication statusPublished - Aug 1 2003

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'CCK-1 receptor blockade for treatment of biliary colic: A pilot study'. Together they form a unique fingerprint.

  • Cite this